Company
Headquarters: Taizhou, China
Employees: 3,586
CN¥11.73 Billion
CNY as of Jan. 1, 2025
US$1.61 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Zhejiang Jiuzhou Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients (API) and intermediates in China and internationally. Its API pipeline comprise central nervous system, non-steroidal, anti-infection, hypoglycemic and antiviral, tumor treatment, anti-depressant, Parkinson, HCV drugs, diabetes, cardiovascular, and respiratory anti-infection drugs. The company also provides asymmetric catalysts and lithium battery materials. Zhejiang Jiuzhou Pharmaceutical Co., Ltd was founded in 1973 and is headquartered in Taizhou, China.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥4.91 B |
| EBITDA | CN¥939.9 M |
| Gross Profit TTM | CN¥1.58 B |
| Profit Margin | 14.20% |
| Operating Margin | 18.63% |
| Quarterly Revenue Growth | -9.20% |
Zhejiang Jiuzhou Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SSE: 603456 wb_incandescent